IPG-LISINOPRIL 20 MG — DIN 02420775
LISINOPRIL : 20 MG · MARCAN PHARMACEUTICALS INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is IPG-LISINOPRIL?
IPG-LISINOPRIL 20 MG contains LISINOPRIL : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02420775, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 13-May-2021. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is IPG-LISINOPRIL used for?
IPG-LISINOPRIL (lisinopril) is indicated in the treatment of essential hypertension and in renovascular hypertension. It may be used alone or concomitantly with thiazide diuretics. Lisinopril is indicated in the management of symptomatic congestive heart failure as adjunctive treatment with diuretics, and where appropriate, digitalis. Lisinopril is indicated in the treatment of hemodynamically stable patients as early as within 24 hours following acute myocardial infarction, to improve survival.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lisinopril cost around the world?
Lisinopril is listed on 17 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 6 | 183 |
| Austria | KVP (Kassenverkaufspreis) | 59 | 62 |
| South Africa | single exit price | 42 | 42 |
| Italy | prezzo al pubblico (classe A) | 10 | 38 |
| Saudi Arabia | public | 33 | 37 |
| Australia | ex-manufacturer | 10 | 36 |
| Sweden | AIP (pharmacy purchase price) | 7 | 20 |
| Luxembourg | reimbursement | 16 | 16 |
| Bahrain | retail (max) | 4 | 15 |
| Greece | producer price (ex-factory) | 15 | 15 |
| Romania | max producer price | 13 | 13 |
| Czechia | max producer price (ex-factory) | 3 | 12 |
| Spain | PVP con IVA (public price) | 8 | 8 |
| Belgium | public | 7 | 7 |
| United Kingdom | hospital | 6 | 6 |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 5 |
| Hungary | producer price (ex-factory) | 3 | 3 |
518 pack listings across 243 brand entries and 15 price bases, refreshed 08 Sep 2026. Ranges span every Lisinopril pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Lisinopril in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
25 holders have a Canadian DIN containing Lisinopril, across 99 DINs, of which 15 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SIVEM PHARMACEUTICALS ULC | 7 | 3 | LISINOPRIL, LISINOPRIL TABLETS | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 3 | TEVA-LISINOPRIL (TYPE P), TEVA-LISINOPRIL (TYPE Z) | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-LISINOPRIL | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 3 | LISINOPRIL (TYPE Z) | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 3 | 3 | ZESTRIL | Sourceable in Canada |
| APOTEX INC | 8 | 0 | APO-LISINOPRIL, APO-LISINOPRIL TABLET (TYPE P) - 10MG, APO-LISINOPRIL TABLET (TYPE P) - 20MG, APO-LISINOPRIL TABLET (TYPE P) - 40MG, APO-LISINOPRIL TABLET (TYPE P) - 5MG, +1 more | No marketed DIN |
| NU-PHARM INC | 8 | 0 | NU-LISINOPRIL | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 6 | 0 | IPG-LISINOPRIL, MAR-LISINOPRIL | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 6 | 0 | RATIO-LISINOPRIL P, RATIO-LISINOPRIL Z | No marketed DIN |
| MERCK CANADA INC | 4 | 0 | PRINIVIL | No marketed DIN |
| LABORATOIRE RIVA INC. | 3 | 0 | RIVA-LISINOPRIL | No marketed DIN |
| MINT PHARMACEUTICALS INC | 3 | 0 | MINT-LISINOPRIL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lisinopril |
|---|---|
| ATC code | C09AA03 |
| AHFS class | 24:32.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02420775 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2420775 |
| Brand name | IPG-LISINOPRIL |
| Generic / active ingredient | LISINOPRIL : 20 MG |
| Market authorization holder | MARCAN PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | C09AA03 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09AA |
| Current status | CANCELLED PRE MARKET |
| Status date | 13-May-2021 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Hypertension: Initial 10mg/day. Heart Failure: Initial 2.5mg/day under supervision. Post-MI: 5mg within 24h, then 5mg at 24h, 10mg at 48h, then 10mg daily.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ACE inhibitors; history of angioedema; pregnancy/nursing; concomitant use with sacubitril/valsartan or aliskiren (in diabetic/renal patients); children <6 years.
Warnings and precautions
Angioedema (can be fatal); symptomatic hypotension (especially volume depleted); dual blockade of RAS; neutropenia/agranulocytosis; risk of fetal injury.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
15 of 99 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LISINOPRIL | 20 MG | TABLET | AURO PHARMA INC | MARKETED | 02394499 |
| AURO-LISINOPRIL | 10 MG | TABLET | AURO PHARMA INC | MARKETED | 02394480 |
| AURO-LISINOPRIL | 5 MG | TABLET | AURO PHARMA INC | MARKETED | 02394472 |
| LISINOPRIL (TYPE Z) | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | 02525208 |
| LISINOPRIL (TYPE Z) | 5 MG | TABLET | SANIS HEALTH INC | MARKETED | 02525186 |
| LISINOPRIL (TYPE Z) | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | 02525194 |
| LISINOPRIL TABLETS | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02554518 |
| LISINOPRIL TABLETS | 5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02554488 |
| LISINOPRIL TABLETS | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02554496 |
| TEVA-LISINOPRIL (TYPE Z) | 20 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02285134 |
2 · Same class — other molecules in ATC C09AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ramipril | ACH-RAMIPRIL · ACT RAMIPRIL · AG-RAMIPRIL · ALTACE · +37 more | 171 | 55 | Yes |
| Perindopril | AG-PERINDOPRIL · AG-PERINDOPRIL ERBUMINE · APO-PERINDOPRIL · APO-PERINDOPRIL ARGININE · +20 more | 81 | 54 | Yes |
| Enalapril | ACT ENALAPRIL · APO-ENALAPRIL · AVA-ENALAPRIL · DOM-ENALAPRIL · +21 more | 100 | 36 | Yes |
| Trandolapril | APO-TRANDOLAPRIL · AURO-TRANDOLAPRIL · MAVIK · MYLAN-TRANDOLAPRIL · +4 more | 40 | 25 | Yes |
| Lisinopril | ACT LISINOPRIL · APO-LISINOPRIL · APO-LISINOPRIL TABLET (TYPE P) - 10MG · APO-LISINOPRIL TABLET (TYPE P) - 20MG · +28 more | 99 | 15 | Yes |
| Captopril | APO-CAPTO TAB 100MG · APO-CAPTO TAB 12.5MG · APO-CAPTO TAB 25MG · APO-CAPTO TAB 50MG · +41 more | 77 | 9 | Yes |
| Cilazapril | APO-CILAZAPRIL · CILAZAPRIL · CO CILAZAPRIL · DOM-CILAZAPRIL · +7 more | 33 | 6 | Yes |
| Fosinopril | APO-FOSINOPRIL · AVA-FOSINOPRIL · FOSINOPRIL · FOSINOPRIL TABLETS · +14 more | 32 | 6 | Yes |
| Quinapril | ACCUPRIL 5MG TAB · ACCUPRIL TAB 10MG · ACCUPRIL TAB 20MG · ACCUPRIL TAB 40MG · +7 more | 32 | 6 | Yes |
| Benazepril | BENAZEPRIL · LOTENSIN 10MG · LOTENSIN 20MG · LOTENSIN 5MG · +1 more | 9 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is IPG-LISINOPRIL called?
The same molecule, Lisinopril, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Omace | Latin | Bahrain, Saudi Arabia |
| Zestril | Latin | Australia, Bahrain |
| Zestril® | Latin | Sweden |
| APO-Lisinopril | Latin | Australia |
| Lisinopril Sandoz | Latin | Australia |
| LISINOPRIL-WGR | Latin | Australia |
| DAPRIL | Latin | Czechia |
| LISINOPRIL | Latin | Brazil |
| AMESOS | Latin | Czechia |
| DIROTON | Latin | Czechia |
| LINOPRIL | Latin | Bahrain |
| LISINO | Latin | Bahrain |
| Lisinopril Ebb | Latin | Sweden |
| Lisinopril STADA® | Latin | Sweden |
| ZINOPRIL | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Lisinopril And Diuretics called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Lisinopril And Diuretics, published to help those searches reach this page.
| Language | Lisinopril And Diuretics |
|---|---|
| Russian Русский | лизиноприл |
| Spanish Español | lisinopril |
| French Français | lisinopril |
| Portuguese Português | lisinopril |
| German Deutsch | Lisinopril |
| Japanese 日本語 | リシノプリル |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.